LCN2

Across TCGA pan-cancer cohorts, LCN2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LCN2 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LCN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LCN2 expression acts as an unfavorable survival marker, although some lineages such as OV and UCEC show a favorable association.

LUAD, OV, and UCEC are the cancer types where LCN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.240	0.741	.002	26	view →
OV	DFS	Tertile	All	0.835	0.479	.024	16	view →
UCEC	OS	Median	All	1.000	0.904	.007	12	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	11	view →
HNSC	OS	Quartile	All	0.889	0.646	.013	9	view →
LSCC	DFS	Tertile	All	0.742	0.353	.048	2	view →
PDAC	OS	Quartile	III,IV	0.454	0.994	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LCN2–LUAD (OS)

Open the LUAD breakdown →